Your browser doesn't support javascript.
loading
Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial.
Kim, S T; Kang, J H; Lee, J; Lee, H W; Oh, S Y; Jang, J S; Lee, M A; Sohn, B S; Yoon, S Y; Choi, H J; Hong, J H; Kim, M-J; Kim, S; Park, Y S; Park, J O; Lim, H Y.
Afiliación
  • Kim ST; Division of Hemato-oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul.
  • Kang JH; Division of Hemato-oncology, Department of Medicine, Gyeongsang National University Hospital, Jinju.
  • Lee J; Division of Hemato-oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul.
  • Lee HW; Division of Hemato-oncology, Department of Medicine, Ajou University School of Medicine, Suwon.
  • Oh SY; Division of Hemato-oncology, Department of Medicine, Dong-A University School of Medicine, Busan.
  • Jang JS; Division of Hemato-oncology, Department of Medicine, Chung-Ang University College of Medicine, Seoul.
  • Lee MA; Division of Hemato-oncology, Department of Medicine, Seoul St Mary's Hospital, Catholic University, Seoul.
  • Sohn BS; Division of Hemato-oncology, Department of Medicine, Sanggye Paik Hospital, Inje University College of Medicine, Seoul.
  • Yoon SY; Division of Hemato-oncology, Department of Medicine, Konkuk University Medical Center, Seoul.
  • Choi HJ; Division of Hemato-oncology, Department of Medicine, Yonsei University College of Medicine, Seoul.
  • Hong JH; Division of Hemato-oncology, Department of Medicine, Incheon St Mary's Hospital, Catholic University, Incheon.
  • Kim MJ; Statistics and Data Center, Research Institute for Future Medicine, Samsung Medical Center, Seoul, South Korea.
  • Kim S; Statistics and Data Center, Research Institute for Future Medicine, Samsung Medical Center, Seoul, South Korea.
  • Park YS; Division of Hemato-oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul.
  • Park JO; Division of Hemato-oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul. Electronic address: oncopark@skku.edu.
  • Lim HY; Division of Hemato-oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul. Electronic address: hoylim@skku.edu.
Ann Oncol ; 30(5): 788-795, 2019 05 01.
Article en En | MEDLINE | ID: mdl-30785198
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias del Sistema Biliar / Protocolos de Quimioterapia Combinada Antineoplásica Tipo de estudio: Clinical_trials Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias del Sistema Biliar / Protocolos de Quimioterapia Combinada Antineoplásica Tipo de estudio: Clinical_trials Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article